title: Current status and future applications of cellular therapies for cancer.
abstract: Therapies based on the use of autologous immune cells are among the best candidates for cancer immunotherapy. Dendritic cell vaccines have demonstrated very encouraging responses for some solid tumors, while in melanoma autologous T-cell therapies have exceeded 70% objective response rates in selected Phase I trials. However, it is clear that a number of barriers exist to the effective, practical application of these therapies. The aim of this article is to consider modifications to such strategies over the last 3 years and the resultant clinical research in autologous dendritic cell vaccines, T-cell therapy and γδ T-cell therapy for cancer.
authors.affiliation: Department of Oncology, Division of Clinical Sciences, St George's University of London, London, UK.
authors.forename: John
authors.initials: J
authors.lastname: Copier
authors.forename: Mark
authors.initials: M
authors.lastname: Bodman-Smith
authors.forename: Angus
authors.initials: A
authors.lastname: Dalgleish
mesh_terms: D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods* / Q000639:trends*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D016692:Receptors, Antigen, T-Cell, gamma-delta